Gain Therapeutics Presents GCase Modulator Data Ahead of Parkinson's Congress
Event summary
- Gain Therapeutics will present oral data on GT-02287, a GCase modulator, at the 3rd International GBA1 Meeting on May 22, 2026.
- Jonas Hannestad, Chief Medical Officer, will present the data during a session focused on pipeline updates.
- Gain management will also attend the 7th World Parkinson’s Congress in Phoenix, AZ, from May 24-27, 2026.
- GT-02287 is currently in a Phase 1b clinical trial for Parkinson’s disease, with initial data showing CNS target engagement and GluSph reduction.
- The Phase 1b trial includes an extension allowing participants to be treated for up to 12 months.
The big picture
Gain Therapeutics' focus on GCase modulation represents a targeted approach to Parkinson's disease, addressing a significant genetic subset (GBA1 mutation carriers) and potentially impacting broader disease progression. The Phase 1b data, while promising, will need to be validated in larger trials to determine if GT-02287 can meaningfully alter the course of the disease and compete within a market attracting substantial investment and innovation.
What we're watching
- Clinical Efficacy
- The 12-month extension of the Phase 1b trial will be critical in assessing whether initial efficacy signals (GluSph reduction, MDS-UPDRS stabilization) are sustained over a longer period and translate to meaningful clinical benefit.
- Regulatory Pathway
- The presentation at the GBA1 Meeting, coupled with the World Parkinson’s Congress attendance, will likely influence investor and regulatory perceptions of GT-02287’s potential, impacting the timeline for potential Phase 2 studies.
- Competitive Landscape
- Given the crowded Parkinson’s disease therapeutic landscape, the ability of GT-02287 to demonstrate a differentiated disease-modifying effect compared to existing and emerging therapies will be essential for long-term commercial success.
Related topics